Drugs / GRT9906
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03776110 | Sep 2004 → Mar 2005 | — | Grünenthal GmbH | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03783910 | Sep 2005 → Oct 2006 | fibromyalgia | Grünenthal GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRT9906 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03776110 ↗ |
| Route | Oral | “40 mg GRT9906 PR tablet oral (minimal release of 80 percent after 480 minutes)” NCT03776110 ↗ |